This site is intended for U.S. healthcare professionals.
Menu
Close
A patient consent signature is required for enrollment. If your patient is unable to sign in your office, they will be contacted for an e-Signature once the Enrollment Form is received.
See full Terms and Conditions.
Forms and resources for eligible patients who have been prescribed VELSIPITY
Forms and resources to help eligible patients access their prescribed medication
Download and complete the enrollment form to connect your patients with support.
Questions? Call 1-800-350-3080 (Monday-Friday, 8 AM-8 PM ET).
To report an adverse event, please call 1-800-438-1985
Pfizer for Professionals 1-800-505-4426
This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.
© 2024 Pfizer Inc. All rights reserved.
VELSIPITY may increase the susceptibility to infections. Life-threatening and rare fatal infections have been reported in association with other sphingosine 1-phosphate (S1P) receptor modulators. Before starting VELSIPITY, obtain a recent (i.e., within 6 months) CBC, including lymphocyte count. Delay initiation of VELSIPITY in patients with an active infection until the infection is resolved. Consider interruption of treatment with VELSIPITY if a patient develops a serious infection. Continue monitoring for infections up to 5 weeks after discontinuing VELSIPITY.
VELSIPITY is indicated for the treatment of moderately to severely active ulcerative colitis (UC) in adults.